The Centers for Medicare and Medicaid Services said it would not cover the medications under Medicare’s Part D coverage.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be ...

The Trump administration on Friday scrapped a Biden administration proposal to have Medicare cover anti-obesity drugs, ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

The Biden administration had proposed late last year coverage of the popular medicines for obesity.

The Centers for Medicare and Medicaid Services (CMS) finalized a Medicare Advantage (MA) rule proposed by the Biden ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The rise of GLP-1 drugs like Ozempic are changing consumer food waste patterns both at home and in restaurant settings.

More than 7 million people would have gained coverage to the medicine, CMS said when it proposed the rule.

The recent decision by the Trump administration to halt a proposal aimed at expanding coverage for anti-obesity medications under Medicare and Medicaid has significant implications for millions of ...